Alkermes News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.02.19	Alkermes Guides FY19 Revenues Higher Than Estimates - Quick Facts (RTTNews)
14.02.19	Alkermes plc Q4 adjusted earnings Beat Estimates (RTTNews)
12.02.19	Ausblick: Alkermes legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
24.12.18	Biotech Stocks Facing FDA Decision In January 2019 (RTTNews)
17.12.18	Alkermes Submits NDA For Diroximel Fumarate - Quick Facts (RTTNews)
29.11.18	Alkermes Reports Positive Topline Results From Phase 3 Study Of ALKS 3831 (RTTNews)
29.10.18	Biotech Stocks Facing FDA Decision In November (RTTNews)
23.10.18	Alkermes Boosts FY18 Adj Earnings, Revenue Outlook - Quick Facts (RTTNews)
23.10.18	Alkermes plc Q3 adjusted earnings Beat Estimates (RTTNews)
21.10.18	Ausblick: Alkermes mit Zahlen zum abgelaufenen Quartal (finanzen.net)
10.09.18	Alkermes Expands Phase 1 Study For ALKS 4230 In Combination With KEYTRUDA (RTTNews)
26.07.18	Alkermes plc Q2 adjusted earnings Beat Estimates (RTTNews)
03.07.18	FDA Nod For ALKS, TRXC Sees 4-fold Increase In Q2 Revenue, BCLI On Watch (RTTNews)
30.06.18	An Ear To The Pharma: 6 Stocks To Watch (ALKS, ZGNX, ACOR...) (RTTNews)
23.06.18	An Ear To The Pharma: 15 Stocks To Watch (AKAO, PTIE, ASNS…) (RTTNews)
06.06.18	Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference (PR Newswire)
06.06.18	Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference (PR Newswire)
06.06.18	Alkermes Receives License Payment From Biogen - Quick Facts (RTTNews)
06.06.18	Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program (PR Newswire)
06.06.18	Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program (PR Newswire)
29.05.18	Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference (PR Newswire)
29.05.18	Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference (PR Newswire)
29.05.18	Biotech Stocks Facing FDA Decision In June (RTTNews)
23.05.18	Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting (PR Newswire)
23.05.18	Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting (PR Newswire)
14.05.18	Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare Conference (PR Newswire)
14.05.18	Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare Conference (PR Newswire)
10.05.18	Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference (PR Newswire)
10.05.18	Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference (PR Newswire)
04.05.18	Alkermes Launches Award Program To Support And Advance Central Nervous System Disorders Research (PR Newswire)
04.05.18	Alkermes Launches Award Program To Support And Advance Central Nervous System Disorders Research (PR Newswire)
03.05.18	Alkermes to Host Webcast and Conference Call to Discuss ALKS 3831 Development Program (PR Newswire)
03.05.18	Alkermes to Host Webcast and Conference Call to Discuss ALKS 3831 Development Program (PR Newswire)
02.05.18	Alkermes' Corporate Presentation to be Webcast at the Deutsche Bank 43rd Annual Health Care Conference (PR Newswire)
02.05.18	Alkermes' Corporate Presentation to be Webcast at the Deutsche Bank 43rd Annual Health Care Conference (PR Newswire)
30.04.18	Alkermes to Present Clinical Data at Upcoming American Psychiatric Association Annual Meeting (PR Newswire)
30.04.18	Alkermes to Present Clinical Data at Upcoming American Psychiatric Association Annual Meeting (PR Newswire)
26.04.18	Alkermes plc Q1 adjusted earnings Miss Estimates (RTTNews)
26.04.18	Alkermes Completes Patient Enrollment in Pivotal Weight Study of ALKS 3831 for Schizophrenia (PR Newswire)
26.04.18	Alkermes Completes Patient Enrollment in Pivotal Weight Study of ALKS 3831 for Schizophrenia (PR Newswire)
26.04.18	Alkermes Plc Reports First Quarter 2018 Financial Results (PR Newswire)
26.04.18	Alkermes Plc Reports First Quarter 2018 Financial Results (PR Newswire)
19.04.18	Alkermes to Host Conference Call to Discuss First Quarter 2018 Financial Results (PR Newswire)
19.04.18	Alkermes to Host Conference Call to Discuss First Quarter 2018 Financial Results (PR Newswire)
17.04.18	ALKS Pulls Off Sweet Surprise, APRI Thrashed, BMY Gets FDA Nod (RTTNews)
16.04.18	MÄRKTE USA/Freundlich - Vorschusslorbeeren für Quartalszahlen (Dow Jones)
16.04.18	MÄRKTE USA/Freundlich - Anleger setzen auf gute Quartalszahlen (Dow Jones)
16.04.18	Alkermes Says U.S. FDA Accepts Review Of NDA For ALKS 5461 - Quick Facts (RTTNews)
16.04.18	Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (PR Newswire)
16.04.18	Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Alkermes PLC

Aktien Top/Flop

Meistgelesene Nachrichten